ClinicalTrials.gg
WithdrawnNCT01214122Updated Jan 29, 2013

A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of Warfarin

A Phase 1 interventional study of AZD9668 and Warfarin in Pharmacokinetics and Pharmacodynamics, sponsored by AstraZeneca. Withdrawn at 2 sites in Sweden. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-29.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The primary purpose of this study is to determine whether the treatment with AZD9668 will affect the metabolism and effect of Warfarin.

02

Conditions studied

  • Pharmacokinetics
  • Pharmacodynamics

Keywords

  • Phase 1
  • Drug-Drug interaction
  • warfarin
  • AZD9668
  • resulting from AZD9668 and Warfarin interaction
  • pharmacokinetics
  • pharmacodynamics
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed (including genotyping screening sample for CYP2C9 and VKORC1) prior to any study specific procedures
  • Subjects must be willing to use a barrier method of , unless their partners are or surgically sterile, or if a female partner is of the subject must use a barrier method of contraception (condom) and the partner must use accepted contraceptive methods (oral contraceptive, implant, long term injectable contraceptive or intrauterine device), from first dose of IP (warfarin and AZD9668) until 3 months after last dose of IP (warfarin and AZD9668)
  • Have a between 19 and 30 kg/m2 (inclusive) and a weight between 50 and 100 kg (inclusive)
  • Be a non-smoker or ex-smoker who has stopped smoking for >6 months prior to Visit 1.

Exclusion criteria

Exclusion Criteria:

  • Any disease or disorder
  • Subject predicted to have high sensitivity to warfarin based on CYP2C9 and VKORC1 genotypes
  • Any clinically relevant abnormal findings in physical examination
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Treatment A

    AZD9668 - 2 x30mg tablets

    Drug: AZD9668

  • Experimental
    Treatment B

    Warfarin - 10 x2.5 mg tablets

    Drug: Warfarin

Interventions

  • 60 mg orally twice daily for 11 days

  • 10 x 2.5 (25) mg orally once daily on day 1 and on day 14

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 1

  2. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 2

  3. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 3

  4. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 4

  5. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 5

  6. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 6

  7. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 7

  8. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 8

  9. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 9

  10. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 10

  11. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 11

  12. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 12

  13. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 13

  14. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 14

  15. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 15

  16. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 16

  17. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 17

  18. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 18

  19. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 19

  20. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 20

  21. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 21

  22. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 22

  23. Pharmacokinetics for (R)- and (S)- Warfarin, measured by maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve (AUC)

    Time frame: Pharmacokinetic (PK) sampling will be performed day 23

  24. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 1

  25. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 2

  26. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 3

  27. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 4

  28. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 5

  29. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 6

  30. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 7

  31. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 8

  32. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 9

  33. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 10

  34. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 11

  35. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 12

  36. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 13

  37. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 14

  38. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 15

  39. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 16

  40. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 17

  41. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 18

  42. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 19

  43. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 20

  44. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 21

  45. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 22

  46. Pharmacodynamics measured by maximum international normalised ratio ( INRmax)

    Time frame: International normalised ratio (INR) sampling will be performed day 23

Secondary outcomes

  1. Pharmacokinetics for AZD9668 measured by Css,max

    Time frame: Range from day 9 to 23

  2. Pharmacokinetics for AZD9668 measured by tss,max

    Time frame: Range from day 9 to 23

  3. Pharmacokinetics for AZD9668 measured by Css,min

    Time frame: Range from day 9 to 23

  4. Pharmacokinetics for AZD9668 measured by CLss/F

    Time frame: Range from day 9 to 23

  5. Severity of Adverse Events as a Measure of Safety and Tolerability

    Time frame: Adverse events will be collected pre-dose, during treatment and at follow up

  6. Number of Participants with Adverse Events as a Measure of Safety and Tolerability

    Time frame: Adverse events will be collected pre-dose, during treatment and at follow up

  7. Pharmacokinetics for (R)- and (S)- Warfarin measured tmax.

    Time frame: Range from day 1 to 23

  8. Pharmacokinetics for (R)- and (S)- Warfarin measured t½.

    Time frame: Range from day 1 to 23

  9. Pharmacokinetics for (R)- and (S)- Warfarin measured CL/F.

    Time frame: Range from day 1 to 23

  10. Pharmacokinetics for (R)- and (S)- Warfarin measured Vz/F.

    Time frame: Range from day 1 to 23

07

Study locations

2 sites
  • Research Site
    Linköping, Sweden
  • Research Site
    Uppsala, Sweden
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2010
First posted
Oct 4, 2010
Start
Nov 2010
Primary completionEst.
Dec 2010
CompletionEst.
Dec 2010
Last update
Jan 29, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01214122
Lead sponsor
AstraZeneca
First posted
Oct 4, 2010
Start date
Nov 2010
Primary completion
Dec 2010 (estimated)
Completion
Dec 2010 (estimated)
Last update
Jan 29, 2013

Study contacts

Christopher D O'Brien, MD, PhD
study director · AstraZeneca R&D
Ingemar Bylesjö, MD
principal investigator · Berzelius Clinical Reseach Centre
Wolfgang Kühn, MD
principal investigator · Quintiles AB, Phase 1 Services

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alvelestat · Warfarin

Start the discussion